Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Dermatology · Basal Cell Carcinoma

The Basics of Your BCC Diagnosis

At a Glance

Basal cell carcinoma is the most common skin cancer and is usually slow-growing, highly treatable, and unlikely to spread to distant organs. Treatment focuses on removing the tumor before it damages nearby tissue, while reducing future UV exposure helps protect the skin.

Receiving a cancer diagnosis is often a shock, and it is completely normal to feel overwhelmed or anxious. However, it is important to know right away that Basal Cell Carcinoma (BCC) is highly treatable, and the vast majority of cases have an excellent prognosis [1][2]. While it is technically a form of cancer, BCC behaves very differently from the types of cancer most people fear.

A Common Diagnosis

BCC is the most common form of skin cancer—and indeed the most common of all cancers—globally [3]. In 2021 alone, it was estimated that there were over 4.4 million new cases worldwide [3]. Because it is so common and rarely life-threatening, many national cancer registries do not even track every case, leading to significant undercounting in official statistics [4][5].

Why BCC is Not Melanoma

One of the most frequent misunderstandings for newly diagnosed patients is confusing BCC with melanoma. While both are skin cancers, they are biologically distinct and behave differently:

  • Metastatic Potential: Melanoma has a higher potential to spread to other organs. BCC, on the other hand, has an extremely low risk of metastasis (spreading to distant parts of the body) [6]. Historical estimates place the rate of metastasis for BCC at an exceedingly rare 0.0028% to 0.55% [7][8].
  • Growth Pattern: BCC is typically a slow-growing tumor that remains local to the site where it started [1]. However, if left untreated, local invasion can be substantial and destruct nearby tissue, cartilage, or bone.
  • Treatment Goals: Because it rarely spreads distantly, the goal of treatment is usually focused on local removal to prevent the tumor from growing larger and damaging nearby structures [9].

The Biology: A Broken “Off Switch”

To understand why BCC forms, it helps to look at the Hedgehog signaling pathway. This is a system in your cells that normally has roles in healthy tissue maintenance. In BCC, a genetic mutation causes this biological switch to get stuck in the “on” position, telling cells to divide and grow when they shouldn’t [10].

Most BCCs involve acquired (somatic) mutations in two specific “gears” of this pathway—meaning these mutations happen only in the tumor cells, and are rarely inherited conditions (with rare exceptions like Gorlin syndrome):

  1. PTCH1: This gene normally acts as a brake on the system. In study profiles, this “brake” is lost or broken in about 73% of BCCs [10].
  2. SMO: This gene acts as an accelerator. In about 20% of study cases, a mutation causes the “accelerator” to be permanently pressed down [10].

When these mutations occur—often alongside acquired alterations to the TP53 gene, which normally helps coordinate the cellular response to DNA damage—the result is the formation of a basal cell tumor [11][12].

The Role of UV Exposure and Other Factors

A primary driver of these genetic mutations is Ultraviolet (UV) radiation from the sun or tanning beds [13]. UV light damages the DNA in your skin cells over time, leading to BCC on “sun-exposed” areas like the face, neck, and scalp [14][15]. However, UV exposure is not the only risk factor; a fair skin phenotype, older age, prior history of skin cancer, and a suppressed immune system also significantly increase risk [16].

While the diagnosis may feel heavy, it is important to remember that this is not a personal failure. By understanding that this is a localized issue driven by well-understood biological pathways, you can move forward with confidence in your treatment plan.

Common questions in this guide

What does a basal cell carcinoma diagnosis mean?
Basal cell carcinoma is the most common skin cancer. It usually grows slowly and stays near where it began, and most cases are highly treatable, but an untreated tumor can damage nearby tissue.
How is BCC different from melanoma?
Both are skin cancers, but melanoma has a greater tendency to spread to other organs. BCC usually remains local, so treatment generally focuses on removing the tumor before it damages nearby tissue.
Can basal cell carcinoma spread to other parts of the body?
Distant spread is possible but extremely rare for BCC. Local growth is the more important concern because an untreated tumor can invade nearby tissue, cartilage, or bone.
What causes BCC, and what raises my risk?
Repeated ultraviolet radiation from sunlight or tanning beds can damage skin-cell DNA and trigger changes that lead to BCC. Fair skin, older age, a previous skin cancer, and a suppressed immune system also increase risk; these factors do not mean you caused the cancer.
How do my BCC’s size, location, and subtype affect treatment?
Because BCC treatment is usually aimed at local removal, a larger or deeper tumor may require more extensive treatment to prevent damage to nearby tissue. Its location and microscopic subtype also help your clinician choose the safest approach.
What is the chance that my BCC will return after treatment?
The chance of recurrence depends on the tumor’s subtype, size, location, and how completely it was removed. Ask your dermatologist what your pathology report shows about recurrence risk and what follow-up schedule is appropriate.
How can I protect my skin after a BCC diagnosis?
Sunlight and tanning-bed ultraviolet exposure are important drivers of BCC, so reducing those exposures is a key prevention step. Ask your clinician for a personalized sun-protection and skin-monitoring plan, especially if you have had skin cancer before.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on skin basal cell carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my pathology report, what specific subtype of BCC do I have, and is it considered a 'low-risk' or 'high-risk' pattern?
  2. 2.How does the location and size of my BCC influence the recommended treatment approach?
  3. 3.What is the likelihood of this specific tumor recurring after treatment?
  4. 4.Are there any specific risk factors or prevention choices I should be aware of to protect my skin moving forward?
  5. 5.Since BCC is different from melanoma, what are the specific long-term risks I should be aware of for this type of cancer?

References

References (16)
  1. 1

    Diagnosis and management of basal cell carcinoma: interdisciplinary consensus statements of Jose R. Reyes Memorial Medical Center, a Department of Health Tertiary Hospital in Manila, Philippines.

    Ligeralde-Bascones KI, Gulmatico-Flores Z, Lim-Bueser HG, et al.

    International journal of dermatology 2023; (62(6)):812-821 doi:10.1111/ijd.16555.

    PMID: 36562635
  2. 2

    Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021.

    Hoashi T, Ishikawa M, Uehara J, et al.

    The Journal of dermatology 2024; (51(4)):e90-e105 doi:10.1111/1346-8138.16944.

    PMID: 38264942
  3. 3

    Global, regional and national burden of skin cancer from 1990 to 2021: Analysis of risk factors and prediction of trends in 2035.

    Sun H, Fu J, Li J, et al.

    Medicine 2026; (105(27)):e49407 doi:10.1097/MD.0000000000049407.

    PMID: 42410801
  4. 4

    Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.

    Venables ZC, Nijsten T, Wong KF, et al.

    The British journal of dermatology 2019; (181(3)):474-482 doi:10.1111/bjd.17873.

    PMID: 30864158
  5. 5

    Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes.

    Correia de Sá TR, Silva R, Lopes JM

    Future oncology (London, England) 2015; (11(22)):3011-21 doi:10.2217/fon.15.246.

    PMID: 26449153
  6. 6

    Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer.

    Hyeraci M, Papanikolau ES, Grimaldi M, et al.

    Biomolecules 2023; (13(7)) doi:10.3390/biom13071067.

    PMID: 37509103
  7. 7

    Metastatic Basal Cell Carcinoma of the Skin: A Comprehensive Literature Review, Including Advances in Molecular Therapeutics.

    Bisceglia M, Panniello G, Galliani CA, et al.

    Advances in anatomic pathology 2020; (27(5)):331-353 doi:10.1097/PAP.0000000000000267.

    PMID: 32618586
  8. 8

    A Rare Report of Lung Metastasis of the Common Non-Melanotic Skin Cancer.

    Shafiepour M, Kiani A, Taghavi K, et al.

    Tanaffos 2018; (17(1)):62-65.

    PMID: 30116282
  9. 9

    Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma.

    Zwanenburg AAJH, Van Houdt WJ, Schrijver AM, et al.

    Acta dermato-venereologica 2025; (105()):adv43240 doi:10.2340/actadv.v105.43240.

    PMID: 41039887
  10. 10

    Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened.

    Pietrobono S, Gagliardi S, Stecca B

    Frontiers in genetics 2019; (10()):556 doi:10.3389/fgene.2019.00556.

    PMID: 31244888
  11. 11

    Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.

    Bonilla X, Parmentier L, King B, et al.

    Nature genetics 2016; (48(4)):398-406 doi:10.1038/ng.3525.

    PMID: 26950094
  12. 12

    Understanding the Molecular Genetics of Basal Cell Carcinoma.

    Pellegrini C, Maturo MG, Di Nardo L, et al.

    International journal of molecular sciences 2017; (18(11)) doi:10.3390/ijms18112485.

    PMID: 29165358
  13. 13

    Cumulative solar ultraviolet radiation exposure and basal cell carcinoma of the skin in a nationwide US cohort using satellite and ground-based measures.

    Little MP, Linet MS, Kimlin MG, et al.

    Environmental health : a global access science source 2019; (18(1)):114 doi:10.1186/s12940-019-0536-9.

    PMID: 31881891
  14. 14

    Trends of cutaneous basal cell carcinoma, squamous cell carcinoma, and melanoma among the Chinese, Malays, and Indians in Singapore from 1968-2016.

    Oh CC, Jin A, Koh WP

    JAAD international 2021; (4()):39-45 doi:10.1016/j.jdin.2021.05.006.

    PMID: 34409390
  15. 15

    Geographic Clusters of Basal Cell Carcinoma in a Northern California Health Plan Population.

    Ray GT, Kulldorff M, Asgari MM

    JAMA dermatology 2016; (152(11)):1218-1224 doi:10.1001/jamadermatol.2016.2536.

    PMID: 27439152
  16. 16

    Known and new facts on basal cell carcinoma.

    Seidl-Philipp M, Frischhut N, Höllweger N, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2021; (19(7)):1021-1041 doi:10.1111/ddg.14580.

    PMID: 34288482

This page is for informational purposes only and does not constitute medical advice. Your dermatologist or cancer specialist should interpret your specific BCC diagnosis, recurrence risk, and treatment options.